D.A. Davidson & CO. Sells 1,299 Shares of Zoetis Inc. (NYSE:ZTS)

D.A. Davidson & CO. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,680 shares of the company’s stock after selling 1,299 shares during the quarter. D.A. Davidson & CO.’s holdings in Zoetis were worth $4,021,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ZTS. AMF Tjanstepension AB increased its stake in Zoetis by 23.4% during the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares during the last quarter. Howard Capital Management Group LLC increased its stake in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Zoetis by 8.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock worth $10,882,000 after acquiring an additional 4,107 shares during the last quarter. Raleigh Capital Management Inc. increased its stake in Zoetis by 128.5% during the third quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock worth $71,000 after acquiring an additional 203 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI grew its stake in shares of Zoetis by 39.6% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 2,590 shares of the company’s stock valued at $507,000 after buying an additional 735 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Up 0.5 %

Zoetis stock opened at $157.38 on Friday. The business has a fifty day moving average of $166.86 and a two-hundred day moving average of $178.14. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $70.47 billion, a P/E ratio of 28.77, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, analysts forecast that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis’s dividend payout ratio is presently 36.56%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Barclays upped their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Piper Sandler cut their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Finally, UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.